Kura Oncology Earnings Calls

Q1 2025 (Upcoming)
Release date May 01, 2025
EPS estimate -$0.510
EPS actual -
Revenue estimate 39.076M
Revenue actual -
Expected change +/- 6.76%
Q4 2024 Beat
-$0.220 (66.15%)
Release date Feb 26, 2025
EPS estimate -$0.650
EPS actual -$0.220
EPS Surprise 66.15%
Revenue estimate 57.962M
Revenue actual 53.883M
Revenue Surprise -7.04%
Q3 2024 Beat
-$0.630 (1.56%)
Release date Nov 07, 2024
EPS estimate -$0.640
EPS actual -$0.630
EPS Surprise 1.56%
Revenue estimate 57.962M
Revenue actual -
Q2 2024 Beat
-$0.590 (6.35%)
Release date Aug 08, 2024
EPS estimate -$0.630
EPS actual -$0.590
EPS Surprise 6.35%
Revenue estimate -
Revenue actual -

Last 4 Quarters for Kura Oncology

Below you can see how KURA performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.

Q2 2024 Beat
Release date Aug 08, 2024
Fiscal end date Jun 30, 2024
Price on release $19.12
EPS estimate -$0.630
EPS actual -$0.590
EPS surprise 6.35%
Date Price
Aug 02, 2024 $19.50
Aug 05, 2024 $18.86
Aug 06, 2024 $19.14
Aug 07, 2024 $18.57
Aug 08, 2024 $19.12
Aug 09, 2024 $18.97
Aug 12, 2024 $18.98
Aug 13, 2024 $19.03
Aug 14, 2024 $19.04
4 days before -1.95%
4 days after -0.418%
On release day -0.785%
Change in period -2.36%
Q3 2024 Beat
Release date Nov 07, 2024
Fiscal end date Sep 30, 2024
Price on release $17.77
EPS estimate -$0.640
EPS actual -$0.630
EPS surprise 1.56%
Date Price
Nov 01, 2024 $16.88
Nov 04, 2024 $17.81
Nov 05, 2024 $17.52
Nov 06, 2024 $17.84
Nov 07, 2024 $17.77
Nov 08, 2024 $17.68
Nov 11, 2024 $17.56
Nov 12, 2024 $18.57
Nov 13, 2024 $17.75
4 days before 5.27%
4 days after -0.113%
On release day -0.506%
Change in period 5.15%
Q4 2024 Beat
Release date Feb 26, 2025
Fiscal end date Dec 31, 2024
Price on release $7.77
EPS estimate -$0.650
EPS actual -$0.220
EPS surprise 66.15%
Date Price
Feb 20, 2025 $8.15
Feb 21, 2025 $8.25
Feb 24, 2025 $7.88
Feb 25, 2025 $7.88
Feb 26, 2025 $7.77
Feb 27, 2025 $7.65
Feb 28, 2025 $7.71
Mar 03, 2025 $7.25
Mar 04, 2025 $7.33
4 days before -4.66%
4 days after -5.66%
On release day -1.54%
Change in period -10.06%
Q1 2025 (Upcoming)
Release date May 01, 2025
Fiscal end date Mar 30, 2025
Price on release -
EPS estimate -$0.510
EPS actual -
Date Price
Apr 16, 2025 $5.75
Apr 17, 2025 $5.90
Apr 21, 2025 $6.18
Apr 22, 2025 $6.31
Apr 23, 2025 $6.37

Kura Oncology Earnings Call Transcript Summary of Q4 2024

Q4 2024

Key Highlights and Developments:

  • Ziftomenib Update:
    • Kura is preparing to submit its first New Drug Application (NDA) for ziftomenib targeting relapsed/refractory NPM1-mutant Acute Myeloid Leukemia (AML) next quarter.
    • The drug has shown promising clinical activity in the KOMET-001 Phase 2 trial, successfully meeting primary endpoints with a 20-30% complete response (CR) rate. Data from this trial will be presented at the upcoming ASCO conference.
    • Kura has achieved alignment with the FDA and EMA on regulatory pathways that could facilitate accelerated approval in both intensive and non-intensive frontline settings.
    • Top-line results for the intensive chemotherapy cohort (KOMET-017-IC) are anticipated in 2028.
  • Market Opportunity:
    • The U.S. market for menin inhibitors in frontline AML is projected to exceed $7 billion annually, underscoring the transformative potential of ziftomenib, particularly considering the high unmet need in AML treatments.
  • Pipeline and Strategic Initiatives:
    • Kura is advancing other product candidates, including KOMET-015, which will evaluate ziftomenib in combination with imatinib for gastrointestinal stromal tumors (GIST), expected to initiate in the first half of 2025.
    • The company is focusing on its farnesyl transferase inhibitor (FTI) programs, particularly KO-2806, which could serve as a companion therapy in combination with various targeted therapies for solid tumors.
  • Financial Overview:
    • Q4 2024 collaboration revenue was $53.9 million from the partnership with Kyowa Kirin, compared to none the previous year.
    • R&D expenses increased to $52.3 million, while general and administrative expenses were $24.1 million.
    • Net loss for Q4 2024 was $19.2 million, significantly reduced from $42.8 million in the previous year.
    • As of December 31, 2024, cash reserves totaled $727.4 million, supporting operations through 2027.
  • Clinical Development Outlook:
    • Upcoming milestones include presenting updates at major medical conferences and results from multiple ongoing trials throughout 2025, enhancing the company's position in AML and solid tumors.
    • Kura is actively exploring partnerships to leverage its compounds in additional therapeutic areas like diabetes, although it remains focused on oncology.
  • Regulatory Engagement and Strategy:
    • Kura's interactions with the FDA regarding MRD-negative CR as a surrogate endpoint have been constructive, minimizing concerns about potential disruptions at the agency due to staffing changes.

Conclusion:

Kura Oncology is well-positioned for significant advancements in its pipeline, particularly with ziftomenib, and is poised for potential accelerated approval and commercialization in AML. The company's strong financial position and strategic collaborations are expected to facilitate ongoing development and enhance shareholder value in the forthcoming years. Investors should monitor upcoming trial results, regulatory developments, and market conditions closely as Kura continues to drive its innovative oncology therapies forward.

Kura Oncology Earnings History

Earnings Calendar

FAQ

When is the earnings report for KURA?
Kura Oncology (KURA) has scheduled its earnings report for May 01, 2025 before the markets open.

What is the KURA price-to-earnings (P/E) ratio?
KURA P/E ratio as of Apr 23, 2025 (TTM) is -3.10.

What is the KURA EPS forecast?
The forecasted EPS (Earnings Per Share) for Kura Oncology (KURA) for the first fiscal quarter 2025 is -$0.510.

What are Kura Oncology's retained earnings?
On its balance sheet, Kura Oncology reported retained earnings of $53.88 million for the latest quarter ending Dec 31, 2024.

What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.

Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.

What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
Click to get the best stock tips daily for free!
ABOUT KURA ONCOLOGY
Kura Oncology
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, includi...
GOLDEN STAR
Ticker Change Signal Date
I
IBTF
$23.34
0.0857% Apr 21
AN
$165.78
1.88% Apr 17
S
SLQD
$49.97
0.0600% Apr 15
B
BNDW
$68.54
0.146% Apr 15
I
ISTB
$48.11
0.187% Apr 15

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE